Litfulo 30 x 50mg

Description

Litfulo 30 x 50mg

The benefits of Litfulo were investigated in a main study involving 718 adults and adolescents over 12 years of age with severe alopecia areata, 261 of whom were given 50 mg Litfulo or placebo (a dummy treatment). All patients had more than 50% hair loss on the scalp before they started treatment. After 24 weeks of treatment, disease symptoms improved in patients given Litfulo: 13% of them were in near remission, meaning that they had more than 90% hair coverage on their scalp, and 23% had more than 80% hair coverage. Such improvements were seen in 1.5% of patients given placebo. After 48 weeks, 31% of patients given Litfulo were in near remission. When asked whether their alopecia had improved, 49% of patients given Litfulo stated that their condition had moderately or greatly improved, compared with 9% of patients given placebo

The results make other medicines almost non tangible.